Abstract：Bladder cancer is one of the most common tumors in the human urogenital system. Currently, the first-line treatment for advanced and metastatic bladder cancer is Cisplatin-based chemotherapy. However, the overall clinical efficacy of Cisplatin is unsatisfactory due to the emergence of drug resistance. With the recent intensive research on circular RNA (circRNA), which regulates downstream mRNA through the regulation of miRNA, it has been found to be involved in the progression of bladder cancer and chemotherapy resistance. Therefore, circRNA may be a potentially promising target for the treatment of bladder cancer. This paper mainly reviewed the mechanism of different circRNA and cisplatin resistance in bladder cancer. These studies will deepen the understanding of the role of the circRNA in the progression of bladder cancer and provide a new entry point for further explore bladder cancer and its Cisplatin resistance mechanisms.
王群 孙雨欣 栾婷 王海峰. circRNA在膀胱癌顺铂耐药中的研究现状及展望[J]. 中国医药导报, 2023, 20(34): 65-68.
WANG Qun SUN Yuxin LUAN Ting WANG Haifeng. Research status and prospect of circRNA in Cisplatin resistance in bladder cancer. 中国医药导报, 2023, 20(34): 65-68.
[1] Sanli O，Dobruch J，Knowles MA，et al. Bladder cancer [J]. Nat Rev Dis Primers，2017，3：17022. [2] Witjes JA，Bruins HM，Cathomas R，et al. European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer：Summary of the 2020 Guidelines [J]. Eur Urol，2021，79（1）：82-104. [3] Milowsky MI，Rumble RB，Booth CM，et al. Guideline on Muscle- Invasive and Metastatic Bladder Cancer（European Association of Urology Guideline）：American Society of Clinical Oncology Clinical Practice Guideline Endorsement [J]. J Clin Oncol，2016，34（16）：1945-1952. [4] Sun K，Wang D，Yang BB，et al. The Emerging Functions of Circular RNAs in Bladder Cancer [J]. Cancers （Basel），2021，13（18）：4618. [5] Cai Z，Li H. Circular RNAs and Bladder Cancer [J]. Onco Targets Ther，2020，13：9573-9586. [6] Eger N，Schoppe L，Schuster S，et al. Circular RNA Splicing [J]. Adv Exp Med Biol，2018，1087：41-52. [7] Rahimi K，Ven?覬 MT，Dupont DM，et al. Nanopore sequen- cing of brain-derived full-length circRNAs reveals circRNA- specific exon usage，intron retention and microexons [J]. Nat Commun，2021，12（1）：4825. [8] Zhou WY，Cai ZR，Liu J，et al. Circular RNA：metabolism，functions and interactions with proteins [J]. Mol Cancer，2020，19（1）：172. [9] Han B，Chao J，Yao H. Circular RNA and its mechanisms in disease：From the bench to the clinic [J]. Pharmacol Ther，2018，187：31-44. [10] Huang Y，Zhang C，Xiong J，et al. Emerging important roles of circRNAs in human cancer and other diseases [J]. Genes Dis，2021，8（4）：412-423. [11] Mu Q，Lv Y，Luo C，et al. Research Progress on the Functions and Mechanism of circRNA in Cisplatin Resistance in Tumors [J]. Front Pharmacol，2021，12：709324. [12] Xie F，Xiao X，Tao D，et al. circNR3C1 Suppresses Bladder Cancer Progression through Acting as an Endogenous Blocker of BRD4/C-myc Complex [J]. Mol Ther Nucleic Acids，2020， 22：510-519. [13] Zhu J，Luo Y，Zhao Y，et al. circEHBP1 promotes lymphan- giogenesis and lymphatic metastasis of bladder cancer via miR-130a-3p/TGFβR1/VEGF-D signaling [J]. Mol Ther，2021，29（5）：1838-1852. [14] Wang F，Fan M，Cai Y，et al. Circular RNA circRIMS1 Acts as a Sponge of miR-433-3p to Promote Bladder Cancer Progression by Regulating CCAR1 Expression [J]. Mol Ther Nucleic Acids，2020，22：815-831. [15] Cong L，Yang Q，Hu C，et al. Current Status of Functional Studies on Circular RNAs in Bladder Cancer and their Potential Role as Diagnostic and Prognostic Biomarkers：A Review [J]. Med Sci Monit，2019，25：3425-3434. [16] Yuan W，Zhou R，Wang J，et al. Circular RNA Cdr1as sen- sitizes bladder cancer to cisplatin by upregulating APAF1 expression through miR-1270 inhibition [J]. Mol Oncol，2019，13（7）：1559-1576. [17] Hansen TB，Jensen TI，Clausen BH，et al. Natural RNA circles function as efficient microRNA sponges [J]. Nature，2013，495（7441）：384-388. [18] Li P，Nijhawan D，Budihardjo I，et al. Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade [J]. Cell，1997，91（4）：479-489. [19] Zhang TM. TRIAP1 Inhibition Activates the Cytochrome c/ Apaf-1/Caspase-9 Signaling Pathway to Enhance Human Ovarian Cancer Sensitivity to Cisplatin [J]. Chemotherapy，2019，64（3）：119-128. [20] Devarajan N，Manjunathan R，Ganesan SK. Tumor hypoxia：The major culprit behind cisplatin resistance in cancer patients [J]. Crit Rev Oncol Hematol，2021，162：103327. [21] Su Y，Yang W，Jiang N，et al. Hypoxia-elevated circELP3 contributes to bladder cancer progression and cisplatin res- istance [J]. Int J Biol Sci，2019，15（2）：441-452. [22] Miyamoto H，Yang Z，Chen YT，et al. Promotion of bladder cancer development and progression by androgen receptor signals [J]. J Natl Cancer Inst，2007，99（7）：558-568. [23] Chen J，Sun Y，Ou Z，et al. Androgen receptor-regulated circFNTA activates KRAS signaling to promote bladder cancer invasion [J]. EMBO Rep，2020，21（4）：e48467. [24] Klochkov SG，Neganova ME，Yarla NS，et al. Implications of farnesyltransferase and its inhibitors as a promising strategy for cancer therapy [J]. Semin Cancer Biol，2019，56：128-134. [25] Kazi A，Xiang S，Yang H，et al. Dual Farnesyl and Gerany- lgeranyl Transferase Inhibitor Thwarts Mutant KRAS-Driven Patient-Derived Pancreatic Tumors [J]. Clin Cancer Res，2019，25（19）：5984-5996. [26] Gong P，Xu R，Zhuang Q，et al. A novel circular RNA （hsa_circRNA_102336），a plausible biomarker，promotes the tumorigenesis by sponging miR-515-5p in human bladder cancer [J]. Biomed Pharmacother，2020，126：110059. [27] Chi BJ，Zhao DM，Liu L，et al. Downregulation of hsa_ circ_0000285 serves as a prognostic biomarker for bladder cancer and is involved in cisplatin resistance [J]. Neopl- asma，2019，66（2）：197-202. [28] Wei W，Sun J，Zhang H，et al. Circ0008399 Interaction with WTAP Promotes Assembly and Activity of the m6A Methylt- ransferase Complex and Promotes Cisplatin Resistance in Bladder Cancer [J]. Cancer Res，2021，81（24）：6142-6156. [29] Jia GX，Lin Z，Yan RG，et al. WTAP Function in Sertoli Cells Is Essential for Sustaining the Spermatogonial Stem Cell Niche [J]. Stem Cell Reports，2020，15（4）：968-982. [30] Huang H，Weng H，Chen J. m6A Modification in Coding and Non-coding RNAs：Roles and Therapeutic Implications in Cancer [J]. Cancer Cell，2020，37（3）：270-288. [31] Li B，Jiang J，Assaraf YG，et al. Surmounting cancer drug resistance：New insights from the perspective of N6-methy- ladenosine RNA modification [J]. Drug Resist Updat，2020， 53：100720.
2023, Vol. 20 
京公网安备 11010502046598号